1L EGFRm+ Lung cancer is rapidly evolving and changing. Tagrisso is leading the pack with ORR of 77% and PFS of 18.9 mos.
However, talking about overall survival, Dacomitinib is currently leading with OS of 34.1 mos. As Tagrioss’s final OS data is yet to be declared, the OS in 1L could reach beyond 40 mos.